

## **Funding Opportunity Announcement**

## TSC Alliance 2025 Biosample Seed Grants

The TSC Alliance announces a funding opportunity for 2025 Biosample Seed Grants to support research using blood, tissue, cells, DNA, and/or RNA from samples in the TSC Biosample Repository. The award may support laboratory supplies, personnel costs, services, or equipment necessary to conduct the proposed research. Funds requested can be up to \$20,000. Funding period is one year. Funding will be distributed in early 2026. Applicants may request a Material Transfer Agreement (MTA) and Draft Award Agreement upon submission of the application to allow institutional tech transfer offices sufficient time to review the agreements.

The TSC Biosample Repository houses human biological materials linked to detailed clinical data in the TSC Natural History Database. High-quality biosamples and their associated clinical data enable researchers to discover biomarkers, establish human cell lines or tissue arrays for drug testing, and search for clues to understand why TSC is so different from person to person.

### As of September 1, 2025, the TSC Biosample Repository has received:

- **528** buccal cell samples for DNA isolation
- 1,266 blood samples from which plasma and white blood cells have been isolated
- 201 tissue samples
- **627** blood samples (PREVeNT, RDCRN) and 389 DNA samples (TACERN) from TSC Clinical Research Consortium projects, some of which may be available via application to the projects' Biosample Use Committee. *Please specify in your application if these samples are of interest.*
- Please see a detailed inventory here

### **REQUIREMENTS/ELIGIBILITY**

- To build the dataset associated with each biosample and avoid duplication of work in the future, applicants will be required to share data generated on each sample back to the TSC Biosample Repository.
  - Data can be embargoed for a period of time to be defined in the Material Transfer Agreement to provide time to publish, protect intellectual property, etc.
- This opportunity is open to all investigators at established academic or research institutions worldwide.
  - Researchers at start-up pharmaceutical or biotech companies are eligible if they are unable to utilize TSC biosamples in absence of seed funding.

- Researchers residing in the United States need not be U.S. citizens to apply.
- We welcome applications from tenure-track faculty or equivalent, non-tenure-track faculty, and postdoctoral (PhD or MD) fellows.

### **APPLICATION COMPONENTS**

Compile the following into a single PDF file and email to Ayat Abi at <a href="mailto:aabi@tscalliance.org">aabi@tscalliance.org</a>, Liz Cassidy, MPH at <a href="mailto:ecassidy@tscalliance.org">ecassidy@tscalliance.org</a> AND <a href="mailto:biosample@tscalliance.org">biosample@tscalliance.org</a> no later than 11:00 pm Eastern (US/Canada) on Monday, November 7, 2025.

### **Required components:**

- 1) Complete the **Application for Biosample Access** located below this FOA. The "Study Information" section may be up to two pages in length to fully explain the rationale, objectives, and experimental design. Preliminary data are encouraged to demonstrate feasibility of the approach. Complete the **Natural History Database Data Request Form** if applicable located below the Application for Biosample Access.
- 2) Include a "Statement of Impact" up to a half-page in length describing how this seed funding will advance your research. For example, where will this lead if the experiment is successful, or how will these results be used to apply for a larger grant?
- 3) Include a **one-page budget and justification** for direct costs requested. Limited salary support may be included if required by the institution, but salary support must be strongly justified given the short-term nature of seed funding.
- 4) Principal investigator's NIH-style biosketch or short CV, not exceeding 5 pages.
- 5) IRB approval letter, exemption letter from an institutional official or department chair, or statement that the project has been submitted to your IRB and is awaiting a decision.

### **EVALUATION CRITERIA**

Criteria used to evaluate and prioritize applications for seed funding will include, but are not necessarily limited to:


- Relevance to TSC. Biosamples may be used in studies together with samples from individuals with related disorders for the mutual benefit of multiple disorders, including TSC. However, biosamples will not be provided for use as "control" samples in studies primarily focused on other disorders.
- Impact on TSC research and the TSC community.
- Leveraging data from the Natural History Database linked to each biosample to enhance experimental design, interpretation of results, and impact of the study.

### **FUNDING NOTICE**

Successful applicants will be notified by Monday, December 15, 2025. Award payment will be distributed by early 2026 once Data Sharing Agreement documents are fully executed.

#### **QUESTIONS**

Please contact biosample@tscalliance.org with any questions.



# Application for Biosample Access: BSR Seed Grants

### **Data Sharing Statement**

Along with the biosamples, you will be entitled to receive any data generated by other investigators using these samples. In return, you are required to share data generated on each sample with the TSC Biosample Repository. Data can be embargoed for a period to be defined in the Material Transfer Agreement to provide time to publish, protect intellectual property, etc. You can describe your data sharing plan in the application below.

$\hfill \square$ Please check here to acknowledge that you have read and understand the data sharin
statement.

## **Application Form**

## **Principal Investigator Information**

First Name:	Middle Name:	Last Name:
Salutation:	Degree(s):	Title:
Phone:	Alt. Phone:	Fax:
Email:	CC Email:	

## **Mailing Address**

Institution:	De	epartment:		
Address Line 1:	Ac	Address Line 2:		
City:	State:	Zip:		
Country:	Institution's Federal	Congressional District:		
Funding source(s) to supp	port the proposed work, incl	uding specific award numbers:		
Date of Request:				
the equity, diversity, and in disclosed or disseminated. The information will not be Gender.  Male	I but is vital to track the TSC nclusion of our research pro- to anyone outside of the St used to decide whether a s	C Alliance's progress toward improving grams. The information will not be eering Committee and the TSC Alliance. specific application is approved or not.  □ Prefer to self-describe: Click or tap		
Ethnicity □Hispanic or Latinx		□Prefer not to disclose		
Shipping Information Lab contact/Recipient:  ☐ Check if the same as PI	Information			
First Name:	Middle Name:	Last Name:		
Salutation:	Degree(s):	Title:		
Phone:	Alt. Phone:	Fax:		
Email:	CC Email:			
Shipping Address  ☐ Check if the same as PI	Information			
Institution:	I	Department:		
Address Line 1:	,	Address Line 2:		

City:	State:	Zip:
Country:		
Study Information Study Title:		
Specific Aims:		
Long-term study objectives (please	e include potential impact to TSC co	mmunity):
Overall Project Summary (please in	nclude experimental design and meth	<u>nods):</u>
Justification for Numbers: Example: volume or quantity of sai applicable.	mples requested. Please include stat	istical power analysis, if
How soon will you use the samples	s once received?:	

Data Sharing - Please describe the specific data elements that will be provided back to the TSC Biosample Repository for each sample analyzed:

<u>Data Sharing – Please describe any other ways you plan to share the data, results, and resources that are generated:</u>

Sample Request Infor	mation: Don	or Deta	ils		
Donor Demographics					
Biological Sex: ☐ Male	$\square$ Female	□ Either			
Race: ☐ Any					
☐ American Indian or Alas	ska Native	☐ Asian	☐ Bla	ck or African	American
☐ Native Hawaiian or Oth	er Pacific Islar	nder 🗆	] White or C	Caucasian	☐ Multi-racial
Age Range:					
Minimum:	Maxim				4-1.
Donor Clinical History (ple	ease list any in	ciusion ai	na exclusio	n requiremen	ts):
Total Number of Donors F	Requested:				
Sample Preparation D	<b>Details</b>				
Blood Prep Type					
☐ Plasma Volum	- '	□mL □	•		
☐ White Blood Cell Pelle	ets	Number	of cells pe	er sample: C	lick or tap here to
enter text.					
☐ Other (please explain):					
Nucleic Acid (please spe	ecify source)				
□ DNA from <b>Blood</b>	□ DNA from	Buccal 9	Swabs	□ DNA fron	n Tissue
Minimum quantity:			laximum qu		
Minimum concentrate	tion:		<del>-</del>	ncentration:	
Minimum volume:			lmL □µL		
Tissue (select all that a	pply; please s	specify t	issue origii	n in 'Other P	reparation Details
below)	, , , ,	,	J		,
☐ Frozen					
☐ FFPE					
☐ Tissue Curls	Thickness:		# of c		
☐ Glass Slides	# of unstaine	d slides:		# H&E staine	ed slides:

## **Other Preparation Details**

Please describe, including specifics as appropriate:

Any other considerations we should be aware of?

Natural History Database (NHD) Data Will your project also use data stored in the NHD?
□ YES □ NO
If VES, please fill out the shortened NHD DATA REQUEST FORM found below

# TSC Natural History Database Data Request Form: BSR Seed Grants

### **Data Variables Requested**

Please check all data variables that you are requesting from the NHD for your Biosample Seed Grant Application.

The categories below list example fields in each category. For a full variable list, please reach out to Ayat Abi at aabi@tscalliance.org.

\*For all data exports, the TSC Alliance exports "age at" specific encounters rather than exporting dates for data privacy. If your project needs dates exported, including date of birth of participant, please check this box and explain below:

Explanation: Click or tap here to enter text. ☐ Cardiovascular ☐ Comorbidities (includes chronic infections, diabetes, autoimmune and more) □ COVID-19 Data (applies only to participants with a confirmed positive test) ☐ Demographics (biological sex, race, ethnicity) □ Dental □ Dermatological ☐ Diagnosis (clinical or molecular) ☐ Family Participation □ Genetics □ Liver ☐ Mortality ☐ Neurological (epilepsy, SEGA, SENs, tubers and associated treatments) ☐ Additional data on a subset of participants in a subproject including SEGA imaging dates/data, epilepsy surgery, SEGA shunt, and VNS. For full variable list, please contact Ayat Abi at aabi@tscalliance.org. ☐ Antiepileptic drugs ("snapshot" – if participant has ever received drug and if it is ongoing) ☐ Neuropsychiatric (intellectual ability, psychiatric disorders, learning disorders, behaviors) ☐ Psychoactive drugs ("snapshot" – if participant has ever received drug and if it is ongoing) ☐ Ophthalmological ☐ Other TSC conditions (non-renal abdominal hamartoma, other TSC-related condition not captured elsewhere) ☐ Perinatal (prenatal history) □ Pulmonary ☐ Rare Conditions

☐ Renal (angiomyolipoma, cysts, polycystic kidneys and associated treatments)

in	Additional data on a subset of participants in a subproject including angiomyolipoma naging dates/data, nephrectomy, eGFR, and serum creatinine. For full variable list, lease contact <i>Ayat Abi at aabi@tscalliance.org.</i>
□ Repro	ductive